Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5779 - Repeated mutKRAS ctDNA measurements in patients with advanced pancreatic cancer patients: kinetics, response prediction and therapy monitoring in comparison to protein-based tumor markers

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Stephan Kruger

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

S. Kruger1, V. Heinemann1, C. Ross2, F. Diehl2, S. Ormanns3, S. Liebmann3, C.B. Westphalen1, M. Haas1, A. Jung3, T. Kirchner3, M. von Bergwelt-Baildon1, S. Holdenrieder4, S. Boeck1

Author affiliations

  • 1 Department Of Internal Medicine Iii And Comprehensive Cancer Center, Ludwig Maximilians University, 81377 - Munich/DE
  • 2 Research And Development, Sysmex Inostics GmbH, 20251 - Hamburg/DE
  • 3 Institute Of Pathology, Ludwig Maximilians University, 80337 - Munich/DE
  • 4 Institute Of Laboratory Medicine, German Heart Center, Technical University of Munich, 80636 - Munich/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5779

Background

The presence of mutated KRAS circulating tumor DNA (mutKRAS ctDNA) in plasma samples has been consistently shown to be a negative prognostic indicator in pancreatic cancer (PC). Only small pilot studies have evaluated the value of serial mutKRAS ctDNA-measurements in PC.

Methods

We used BEAMing technology to determine levels of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 in 284 plasma samples of 54 patients with advanced PC receiving gemcitabine-based first-line chemotherapy. Absolute levels and kinetics of mutKRAS ctDNA, CA 19-9, CEA and CYFRA 21-1 were correlated to radiological response, progression free- and overall survival.

Results

mutKRAS ctDNA was present in a majority of advanced PC patients (n = 36/54, 67%) and indicated tissue KRAS mutation status with a high sensitivity (74%) and specificity (100%). Presence of mutKRAS ctDNA, as well as higher levels of CA 19-9, CEA and CYFRA 21-1 at treatment initiation were significantly correlated to an adverse overall survival. During therapy, changes in mutKRAS ctDNA levels were more rapid and pronounced than changes in protein-based tumor markers. Kinetics of mutKRAS ctDNA were an early indicator of response to therapy, while there was no significant correlation between kinetics of CA 19-9, CEA or CYFRA 21-1 and response to chemotherapy during the first four weeks of treatment. Repeated mutKRAS ctDNA measurements during follow-up indicated progressive disease with high sensitivity (84%) and specificity (100%).

Conclusions

mutKRAS ctDNA kinetics appear to be a powerful and highly specific tool in early response prediction and therapy monitoring of advanced PC patients receiving chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Stephan Kruger, Stefan Holdenrieder, Stefan Boeck.

Funding

Sysmex Inostics.

Editorial Acknowledgement

Disclosure

C. Ross, F. Diehl: Employee: Sysmex Inostics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.